In the United States alone, one of four cancer deaths occur from lung cancer and there are over 8 million individuals considered to be at high-risk due to cigarette smoking and other behaviors. It's well known that early detection of cancer significantly improves survival of this disease, however a lack of lung cancer screenings and analysis precludes fast results at a low cost.
This technology includes three cell lines of dopaminergic neurons derived from human induced pluripotent stem cell (iPSC) line BC1, human iPSG line X1 and human embryonic stem cell (hESC) line H14 to be utilized in neurology research. These cell lines will be used for to study the biology of brain development and may also be used to test different characterization and differentiation assays. The dopaminergic neurons and/or their derivatives may also be used as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases.
This technology includes three distinct cell lines of motor neuron progenitors, derived from different sources: human induced pluripotent stem cell (iPSC) line BC1, human iPSC line X1, and human embryonic stem cell (hESC) line H14. These cell lines hold significant potential for multiple diagnostic and therapeutic applications. A key advantage of these cell lines is the commercial availability of their starting materials (iPSC-BC1, iPSC-X1, and hESC-H14), which are not restricted in terms of usage of their derivatives.
This technology involves an innovative method for differentiating neural stem cells (NSCs) into neurons, primarily for use in basic science research and in developing therapies for brain and spinal cord disorders. Existing methods for generating neurons from NSCs typically result in high efficiency but low survival rates, especially when neurons are dissociated and regrown. This new method utilizes Life Technologies StemPro embryonic stem cell serum-free medium, which significantly enhances differentiation efficiency into neurons with minimal cell death.
This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells.
This technology includes a novel plasmid design for cell immortalization. It uniquely combines the conditional activation of human telomerase and c-myc genes through cumate addition, a method distinct from traditional immortalization techniques which commonly use SV40 T-antigen, telomerase, or c-myc. This plasmid also includes a GFP reporter and a puromycin resistance gene, enhancing the efficiency of the immortalization process.
This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization.
This technology includes a mouse model of Pompe disease, created by targeted inactivation of the acid alpha-glucosidase gene, to test novel therapies. Pompe disease is a severe muscle disorder that affects people at any age. It is a rare genetic disease caused by a deficiency of a lysosomal enzyme acid alpha-glucosidase. The enzyme degrades glycogen to glucose in the lysosomes. The deficiency leads to accumulation of glycogen in multiple organs, but cardiac and skeletal muscles are most severely affected.
This technology includes antibodies against TL 1A for the inhibition of TL 1A-DR3 interactions for the diagnosis and treatment of various autoimmune diseases. Through the use of our developed hamster anti-mouse and mouse anti-human monoclonal antibodies, we’ve demonstrated that treatment with anti-mouse TL 1A prevented collagen-induced arthritis and TNBS-induced colitis NEED TO UPDATE